700 patients with AMI;several demographics, clinical and analytical parameters were collected, and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cardiovascular disease of different severity. Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established "circulatory integration" diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute ischemic cardiovascular diseases.

500 patients with acute ischemic; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cerebrovascular disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established "circulatory integration" diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases.

500 patients with acute lower limb ischemia; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in lower limb ischemia disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established "circulatory integration" diagnosis and treatment evaluation system of lower limb ischemia disease with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases.

200 healthy volunteers were included as controls

Acute Myocardial Infarction

Acute Ischemic Stroke

Ischemic Cardiovascular Disease

Second Affiliated Hospital of Xi'an Jiaotong University

Shaanxi Provincial People's Hospital

First Affiliated Hospital Xi'an Jiaotong University

DSS's Role in Evaluating the Diagnosis and Treatment System of Ischemic Cardiovascular and Cerebrovascular Diseases

The Research on DSS in Evaluating the Diagnosis and Treatment System of Acute Ischemic Cardiovascular and Cerebrovascular Diseases

Incidence of disease recurrence，including acute myocardial infarction, ischemic stroke and acute lower limb ischemia.

All deaths were considered to have been from cardiac causes unless a explicit noncardiac cause could be documented.

All deaths were taken into account unless there is a definite cause of accidental death.

p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks

Dyslipidemias

Hypertension

Vasodilation

Oxidative Stress

Inflammation

3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks

Salvia miltiorrhiza extract

3 placebo capsules, twice daily for four consecutive weeks

Placebo

Radboud University Nijmegen Medical Centre

Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen)

A Double Blind, Randomized Placebo-controlled Cross-over Study on the Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen) in Patients With Hypertension and Hyperlipidemia.

Blood tests: lipids, in particular LDL-cholesterol.

Radboud University

Standard acute coronary syndrome treatment as per hospital protocol
Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min
In-hospital oxygen as per hospital protocol

Standard acute coronary syndrome treatment as per hospital protocol
No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.

Coronary Artery Disease

Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min
In-hospital oxygen as per hospital protocol

Oxygen therapy

No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.

No oxygen therapy

Peninsula Private Hospital

Alfred Hospital

Western Hospital

Royal Melbourne Hospital

St Vincents Hospital

Austin Hospital

Ambulance Victoria

Box Hill Hospital

Monash Medical Centre

Frankston Hospital

Air Verses Oxygen In myocarDial Infarction Study

A Randomised Controlled Trial of Oxygen Therapy in Acute Myocardial Infarction (AVOID - Air Verses Oxygen In myocarDial Infarction Study)

The primary end-point for the study will be infarct size at hospital discharge which will be ascertained by the routinely collected cardiac biomarkers during hospital admission such as cardiac troponin I (cTnI) and creatine kinase (CK)Infarct size will be evaluated via blood test on admission and then 6 hourly tests for 48 hours and 12 hourly measurements between 48 hours and 72 hours. Infarct size will be measured by:
Mean and peak cTnI
Mean and peak CK
The area under the curve of CK and cTnI release over the first 72 hours of reperfusion.

TIMI - Thrombolysis in Myocardial infarction score

Death, recurrent myocardial infarction, and re-hospitalization measured at 6 months

Magnetic resonance imaging (MRI) measurement of infarct size as percent of area at risk determined with T2-weighted MRI (in small sub set of patients) at day 4 and repeated at 6 months.

salvia eremophila/infarkts

DSS's Role in Evaluating the Diagnosis and Treatment System of Ischemic Cardiovascular and Cerebrovascular Diseases

Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen)

Air Verses Oxygen In myocarDial Infarction Study

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne